» Articles » PMID: 38604203

The Burden of Neurological Conditions in North Africa and the Middle East, 1990-2019: a Systematic Analysis of the Global Burden of Disease Study 2019

Overview
Specialty Public Health
Date 2024 Apr 11
PMID 38604203
Affiliations
Soon will be listed here.
Abstract

Background: The burden of neurological conditions in north Africa and the Middle East is increasing. We aimed to assess the changes in the burden of neurological conditions in this super-region to aid with future decision making.

Methods: In this analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 data, we examined temporal trends of disability-adjusted life-years (DALYs; deaths and disabilities combined), deaths, incident cases, and prevalent cases of 14 major neurological conditions and eight subtypes in 21 countries in the north Africa and the Middle East super-region. Additionally, we assessed neurological DALYs due to 22 potentially modifiable risk factors, within four levels of classification, during the period 1990-2019. We used a Bayesian modelling estimation approach, and generated 95% uncertainty intervals (UIs) for final estimates on the basis of the 2·5th and 97·5th percentiles of 1000 draws from the posterior distribution.

Findings: In 2019, there were 441·1 thousand (95% UI 347·2-598·4) deaths and 17·6 million (12·5-24·7) neurological DALYs in north Africa and the Middle East. The leading causes of neurological DALYs were stroke, migraine, and Alzheimer's disease and other dementias (hereafter dementias). In north Africa and the Middle East in 2019, 85·8% (82·6-89·1) of stroke and 39·9% (26·4-54·7) of dementia age-standardised DALYs were attributable to modifiable risk factors. North Africa and the Middle East had the highest age-standardised DALY rates per 100 000 population due to dementia (387·0 [172·0-848·5]), Parkinson's disease (84·4 [74·7-103·2]), and migraine (601·4 [107·0-1371·8]) among the global super-regions. Between 1990 and 2019, there was a decrease in the age-standardised DALY rates related to meningitis (-75·8% [-81·1 to -69·5]), tetanus (-88·2% [-93·9 to -76·1]), stroke (-32·0% [-39·1 to -23·3]), intracerebral haemorrhage (-51·7% [-58·2 to -43·8]), idiopathic epilepsy (-26·2% [-43·6 to -1·1]), and subarachnoid haemorrhage (-62·8% [-71·6 to -41·0]), but for all other neurological conditions there was no change. During 1990-2019, the number of DALYs due to dementias, Parkinson's disease, multiple sclerosis, ischaemic stroke, and headache disorder (ie, migraine and tension-type headache) more than doubled in the super-region, and the burden of years lived with disability (YLDs), incidence, and prevalence of multiple sclerosis, motor neuron disease, Parkinson's disease, and ischaemic stroke increased both in age-standardised rate and count. During this period, the absolute burden of YLDs due to head and spinal injuries almost doubled.

Interpretation: The increasing burden of neurological conditions in north Africa and the Middle East accompanies the increasing ageing population. Stroke and dementia are the primary causes of neurological disability and death, primarily attributable to common modifiable risk factors. Synergistic, systematic, lifetime, and multi-sectoral interventions aimed at preventing or mitigating the burden are needed.

Funding: Bill & Melinda Gates Foundation.

Translations: For the Persian, Arabic and Turkish translations of the abstract see Supplementary Materials section.

Citing Articles

Global, regional, and national burden of tobacco-related neurological disorders from 1990 to 2021: Trends and future projections.

Zhang C, An Z, Jiang J, Ge J, Huang W, Pei J Tob Induc Dis. 2025; 23.

PMID: 40078231 PMC: 11897908. DOI: 10.18332/tid/201966.


Global, regional, and national burden of acute lymphoblastic leukemia in children: Epidemiological trends analysis from 1990 to 2021.

Hu Y, Liu Y, Fu J, Liu Y, Wang H, Song Y iScience. 2024; 27(12):111356.

PMID: 39717082 PMC: 11664140. DOI: 10.1016/j.isci.2024.111356.


A Comprehensive Overview of the Current Status and Advancements in Various Treatment Strategies against Epilepsy.

Waris A, Siraj M, Khan A, Lin J, Asim M, Alhumaydh F ACS Pharmacol Transl Sci. 2024; 7(12):3729-3757.

PMID: 39698272 PMC: 11650742. DOI: 10.1021/acsptsci.4c00494.


Need for neurorehabilitation in the Middle East and North Africa from 1990 to 2021: an analysis based on the global burden of disease study.

Hedayati F, Montazeri A, Sarasyabi M, Darijani S, Kayyal M, Nakhostin-Ansari A Ann Med Surg (Lond). 2024; 86(11):6422-6432.

PMID: 39525781 PMC: 11543145. DOI: 10.1097/MS9.0000000000002583.


Effectiveness of Vitamin D on Neurological and Mental Disorders.

AlGhamdi S Diseases. 2024; 12(6).

PMID: 38920563 PMC: 11202759. DOI: 10.3390/diseases12060131.

References
1.
Avan A, Hachinski V . Brain health: Key to health, productivity, and well-being. Alzheimers Dement. 2021; 18(7):1396-1407. DOI: 10.1002/alz.12478. View

2.
Alladi S, Hachinski V . World dementia: One approach does not fit all. Neurology. 2018; 91(6):264-270. DOI: 10.1212/WNL.0000000000005941. View

3.
Owolabi M, Thrift A, Mahal A, Ishida M, Martins S, Johnson W . Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health. 2021; 7(1):e74-e85. PMC: 8727355. DOI: 10.1016/S2468-2667(21)00230-9. View

4.
Jagust W . The changing definition of Alzheimer's disease. Lancet Neurol. 2021; 20(6):414-415. DOI: 10.1016/S1474-4422(21)00077-6. View

5.
. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022; 9(2):137-150. PMC: 8776563. DOI: 10.1016/S2215-0366(21)00395-3. View